Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

2024-511151-18-01 Protocol NL202100762 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 2 Jan 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol NL202100762

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 20
Countries 1
Sites 1

Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2

Key facts

Sponsor
Universitair Medisch Centrum Groningen
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
2 Jan 2025 → ongoing
Decision date (initial)
2024-11-25
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511151-18-01
EudraCT number
2021-005950-27

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitair Medisch Centrum Groningen

Sponsor organisation
Universitair Medisch Centrum Groningen
Address
Hanzeplein 1
City
Groningen
Postcode
9713 GZ
Country
Netherlands

Scientific contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
I.Kraai

Public contact point

Organisation
Universitair Medisch Centrum Groningen
Contact name
I.Kraai

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 20 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Groningen
Hematology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-01-02 2025-01-02

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-16 Netherlands Acceptable
2024-11-25
2024-11-25